GSK Is First To Share Cancer Drug Patents With Poor Countries
This article was originally published in SRA
Executive Summary
GlaxoSmithKline PLC intends to make a big splash in the Medicines Patent Pool as the first company to share its future cancer drug patents for development of generic drugs in least developed and low-income countries and certain middle-income countries1.
You may also be interested in...
Will UN Report On Access To Medicines Change Anything?
Industry opposes interference with intellectual property rights but is open to compulsory licensing and delinking R&D cost to drug prices in limited situations.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.